Tubulis GmbH
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Holding
- Established
- 2012-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.tubulis.com
First in Human Study of TUB-030 in Patients with Advanced Solid Tumors
Phase 1
Recruiting
- Conditions
- Advanced Solid TumorsHNSCCSCLCNSCLCTNBC - Triple-Negative Breast CancerCRC
- Interventions
- First Posted Date
- 2024-10-24
- Last Posted Date
- 2025-01-10
- Lead Sponsor
- Tubulis GmbH
- Target Recruit Count
- 130
- Registration Number
- NCT06657222
- Locations
- 🇺🇸
NEXT Oncology Austin, Austin, Texas, United States
🇺🇸NEXT Oncology - Dallas, Irving, Texas, United States
🇺🇸NEXT Oncology - San Antonio, San Antonio, Texas, United States
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
- First Posted Date
- 2024-03-12
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Tubulis GmbH
- Target Recruit Count
- 100
- Registration Number
- NCT06303505
- Locations
- 🇩🇪
Charité Universitätsmedizin Berlin, Berlin, Germany
🇪🇸NEXT Oncology Madrid, Madrid, Spain
🇬🇧Guy's Hospital, London, United Kingdom
© Copyright 2025. All Rights Reserved by MedPath